57 ± 2 94 ppm by the end of the oxidation trial, and was comparab

57 ± 2.94 ppm by the end of the oxidation trial, and was comparable to values obtained for P (100.27 ± 3.56 ppm; P > 0.05). 60 km performance trial Performance trial measures Whilst all participants attempted the 60 km performance trial, during the P condition, 8 athletes were unable to finish demonstrating the exhaustive nature of the PLX4032 price protocol. In contrast,

all participants completed the performance trial whilst consuming both carbohydrate test beverages. Statistical analysis was therefore carried out on all finishers (n = 6) for comparison across trials. Relative differences in performance times between beverages are shown in Figure 5. Additionally, inclusion of all finishers (n = 14) for the two test beverages are shown for interest. Figure 5 Relative differences in 60 km performance times between beverages. Figure 5 indicates the difference in performance times during the preloaded 60 km time trial when test

beverages were compared for all finishers. The final column is included to demonstrate that all participants completed the test when consuming carbohydrate beverages. P, Placebo; MD, maltodextrin beverage; MD + F, maltodextrin-fructose beverage. Data are presented as mean ± SE; comparisons made for finishers of all trials (first three columns: n = 6) and between test beverages for all finishers (end column: n = 14) *denotes significant difference between relative beverages (P < 0.05). Performance times were significantly faster with MD + F compared OSI-906 concentration with MD and P (5722.8 ± 284.1 seconds v 6165.0 ± 257.9 seconds v 6117.5 ± 358.0 seconds respectively; P < 0.05). In absolute terms, performance times significantly Etofibrate improved with MD + F compared with both MD (by 7 min 22 s ± 1 min 56 s, or 7.2%) and P (by 6 min 35 s ± 2 min 33 s, or 6.5%, P < 0.05) over 60 km. No difference was observed for performance times

between MD and P (P > 0.05). The difference observed between MD + F and MD was further noted when assessment of all 14 finishers was separately undertaken (5868.36 ± 151.31 seconds for MD + F v 6217.14 ± 150.93 seconds for MD; P = 0.001). In a similar manner, relative differences in mean power output was significantly different for MD + F compared to both MD and P for the performance trial (P < 0.03; Figure 6). Mean power output was 14.9% greater with MD + F compared to MD (227.0 ± 23.2 W v 197.6 ± 21.6 W, P = 0.029), and 13.0% greater with MD + F compared to P (227.0 ± 23.2 W v 201.0 ± 22.4 W, P = 0.025). No difference was observed for performance times between MD and P (P > 0.05). The difference observed between MD + F and MD was further noted when assessment of all 14 finishers was separately undertaken (234.0 ± 12.0 W for MD + F v 204.3 ± 11.1 W for MD; P = 0.001). Figure 6 Relative differences in average power output between beverages during the performance trial.

Comments are closed.